Journal article

Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition

G Chetelat, VL Villemagne, N Villain, G Jones, KA Ellis, D Ames, RN Martins, CL Masters, CC Rowe

Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2012


Funding Acknowledgements

Study funding: Supported by the Commonwealth Scientific Industrial Research Organization through the Australian Imaging, Biomarkers and Lifestyle flagship study of aging, the Austin Hospital Medical Research Foundation, Neurosciences Victoria, and the University of Melbourne.Dr. Chetelat reports no disclosures. Dr. Villemagne serves as a consultant for Bayer Schering Pharma; serves as an Associate Editor for the Journal of Alzheimer's Disease; and receives research support from CSIRO (AIBL sponsor). Dr. Villain, G. Jones, and Dr. Ellis report no disclosures. Dr. Ames has served on scientific advisory boards for Novartis, Janssen, and Pfizer Inc; has received funding for travel and/or speaker honoraria from Janssen, Lundbeck Inc., and Pfizer Inc; serves as Editor-in-Chief of International Psychogeriatrics; receives publishing royalties for Dementia, 4th ed. (Hodder, 2010) and Guide to Psychiatry of Old Age (Cambridge University Press, 2010); and receives research support from Eli Lilly and Company, GlaxoSmithKline, Forest Laboratories, Inc., Novartis, and CSIRO (AIBL study). Dr. Martins serves as Senior Editor of the Journal of Alzheimer's Disease; serves as a consultant for and holds stock in Alzhyme; and receives research support from CSIRO. Dr. Masters serves on the editorial advisory boards of American Journal of Alzheimer's Disease and Other Dementias, Annals of Neurosciences, Archives of Neurology, Ageing, Current Alzheimer Research, Dementia and Geriatric Cognitive Disorders, International Journal of Biochemistry and Cell Biology, Journal of Alzheimer's Disease, Journal of Clinical Neuroscience, Journal of Molecular Neurodegeneration, Molecular Psychiatry, Neurodegenerative Diseases, Neuropathology, and Research and Perspectives in Alzheimer's Disease. Dr. Rowe serves on scientific advisory boards for Bayer Schering Pharm, Elan Corporation, AstraZeneca, and GE Healthcare; has received speaker honoraria from Bayer Schering Pharma and Pfizer Inc; and receives research support from Bayer Schering Pharma, Avid Radiopharmaceuticals, Inc., the Alzheimer's Association, the Alzheimer's Drug Discovery Foundation, and CSIRO (AIBL sponsor).